Join me at the Global Longevity Summit this October. Use code BEYONDTOMORROW for 10% off your ticket: https://informaconnect.com/global-longevity-summitWhat if the key to living longer, healthier lives wasn’t a pill, diet, or workout—but rewriting our DNA? In this episode of Longevity Unpacked, we explore gene therapy with Liz Parrish, “patient zero” for longevity treatments and founder of BioViva, and Boyang Wang, investor and founder of Immortal Dragons, backing cutting-edge biotech companies.Liz and Boyang take us inside the science, ethics, and future potential of gene therapy—from curing genetic diseases to extending healthspan. They share personal experiences, discuss regulatory challenges, and explain why billionaires may be leading the way for everyone else.We also explore the economics: could gene therapy cost less than cancer treatment by 2040? Could it even become free? And what would it mean when therapies could boost muscle, brain function, telomeres, and resistance to age-related diseases?Whether you’re curious about the science, excited for the future of medicine, or wondering when these treatments might be available, this episode gives a clear view of the opportunities—and risks—of gene therapy.📌What You’ll Learn in This Episode:What gene therapy actually is, explained in simple termsThe difference between monogenic and polygenic therapiesLiz Parrish’s personal journey as the first patient to undergo gene therapy for longevityWhy Boyang Wang decided to try gene therapy and invest in the spaceThe current state of regulation and approval worldwideHow delivery methods (vectors vs plasmids) change effectivenessThe role of billionaires as early test subjects for longevity treatmentsEthical questions around enhancement, embryos, and “playing God”How gene therapy could reshape healthcare costs by 2040Practical advice for patients, investors, and anyone interested in the future of longevity⏱ Episode Timestamps0:00 – Introduction & Liz’s journey as patient zero 2:08 – Why gene therapy could become essential for survival 5:00 – How gene therapy actually works (explained simply) 10:00 – The difference between monogenic and polygenic therapies 13:15 – Liz’s first treatments and why she took the risk 18:05 – Boyang’s personal motivation for trying gene therapy 23:34 – Vectors vs plasmids: why delivery matters 28:17 – Risks of moving too fast—or too slow—with regulation 33:29 – Billionaires as test subjects: ethical or essential? 36:11 – Will gene therapy cost less than cancer drugs by 2040? 42:03 – Will we see approved longevity therapies by 2030? 47:26 – Gene therapy and the ethics of embryonic editing 53:39 – Longevity, AI, and the future of human intelligence 57:20 – The biggest risks to the gene therapy industry today 1:03:38 – Special interests vs patient access: the real battle 1:07:47 – Advice for newcomers to the gene therapy space 1:10:13 – Boyang’s advice for investors in longevity 1:11:35 – Closing thoughts and next episode teaser🎙 Hosted by Julian Issa 📸 Instagram: @thebeyondtomorrowpodcast 🌐 Website: www.beyondtomorrowpodcast.com 📩 Email: [email protected] 🎧 Subscribe on Spotify, Apple, and YouTube for more stories from the edge of what’s possible.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related